Explore how proteomics in drug discovery supports drug target identification, biomarker discovery and the unearthing of safer therapeutics.
A drug for pulmonary fibrosis created using artificial intelligence (AI) is showing early promise in patients.
Three posters to be presented featuring pre-clinical data of potential best-in-class FGFR3 selective inhibitor, SMARCA2 selective inhibitor, and ...
EDINBURGH and CAMBRIDGE, United Kingdom, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in ...
AI has advanced molecule design, yet synthetic feasibility remains a bottleneck. Chemistry-first approaches offer a practical ...
Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces that its Chief Scientific Officer, Philip Beer, will be presenting data on the ...
The drug development pipeline is a costly and lengthy process. Identifying high-quality "hit" compounds—those with high ...
Genomics unveils Mystra at ASHG 2025—an AI genetics platform to accelerate drug discovery and clinical validation using large-scale genetic data.
SNS Insider projects the U.S. Drug Discovery Market to grow from USD 24.53 Billion in 2025 to USD 48.97 Billion by 2033, at a CAGR of 9.74%.Austin, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Drug Discovery ...
In the rapidly evolving pharmaceutical landscape, drug discovery services have become a pivotal axis around which innovation, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results